Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Postprint
DOI
PMC
 |
Open Access Green |
as soon as is submitted to ZB.
Metabolic network failures in Alzheimer's disease-A biochemical road map.
Alzheimers Dement. 13, 965-984 (2017)
INTRODUCTION: The Alzheimer's Disease Research Summits of 2012 and 2015 incorporated experts from academia, industry, and nonprofit organizations to develop new research directions to transform our understanding of Alzheimer's disease (AD) and propel the development of critically needed therapies. In response to their recommendations, big data at multiple levels are being generated and integrated to study network failures in disease. We used metabolomics as a global biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance. METHODS: Fasting serum samples from the Alzheimer's Disease Neuroimaging Initiative (199 control, 356 mild cognitive impairment, and 175 AD participants) were analyzed using the AbsoluteIDQ-p180 kit. Performance was validated in blinded replicates, and values were medication adjusted. RESULTS: Multivariable-adjusted analyses showed that sphingomyelins and ether-containing phosphatidylcholines were altered in preclinical biomarker-defined AD stages, whereas acylcarnitines and several amines, including the branched-chain amino acid valine and α-aminoadipic acid, changed in symptomatic stages. Several of the analytes showed consistent associations in the Rotterdam, Erasmus Rucphen Family, and Indiana Memory and Aging Studies. Partial correlation networks constructed for Aβ1-42, tau, imaging, and cognitive changes provided initial biochemical insights for disease-related processes. Coexpression networks interconnected key metabolic effectors of disease. DISCUSSION: Metabolomics identified key disease-related metabolic changes and disease-progression-related changes. Defining metabolic changes during AD disease trajectory and its relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
9.478
2.528
157
222
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Acylcarnitines ; Alzheimer's Disease ; Biochemical Networks ; Biomarkers ; Branched-chain Amino Acids ; Dementia ; Metabolism ; Metabolomics ; Metabonomics ; Pharmacometabolomics ; Pharmacometabonomics ; Phospholipids ; Precision Medicine ; Serum ; Sphingomyelins ; Systems Biology; Mild Cognitive Impairment; Pittsburgh Compound-b; Neurodegenerative Disorders; Mass-spectrometry; Older-adults; Mouse Model; Brain; Biomarker; Insulin; Plasmalogen
Language
Publication Year
2017
HGF-reported in Year
2017
ISSN (print) / ISBN
1552-5260
e-ISSN
1552-5279
Journal
Alzheimer's & Dementia
Quellenangaben
Volume: 13,
Issue: 9,
Pages: 965-984
Publisher
Elsevier
Publishing Place
New York, NY [u.a.]
Reviewing status
Peer reviewed
POF-Topic(s)
30505 - New Technologies for Biomedical Discoveries
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-503700-001
WOS ID
WOS:000408861400002
Scopus ID
85015733333
PubMed ID
28341160
Erfassungsdatum
2017-06-19